Direxion Daily TSLA Bull 2X Shares vs Vir Biotechnology Inc. Common Stock — how do they compare? Direxion Daily TSLA Bull 2X Shares trades at $9.27 (market cap $3.84B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Direxion Daily TSLA Bull 2X Shares is far larger — about 2.1× Vir Biotechnology Inc. Common Stock's market cap, and Vir Biotechnology Inc. Common Stock is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily TSLA Bull 2X Shares for 15 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| TSLL | VIR | |
|---|---|---|
Market Cap | $3.84B | $1.80B |
Volume | 36,217,346 | 1,782,836 |
Sector | Leveraged / Inverse | Health |
52-Week High | $23.03 | $11.78 |
52-Week Low | $6.74 | $5.12 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | — | $1.36B |
Signals from Pluang's Aura AI — not financial advice
TSLL, the Direxion Daily TSLA Bull 2X Shares ETF, trades at $10.00, down 1.48% on the day, reflecting amplified exposure to Tesla's volatility. The technical outlook is mixed with a neutral overall signal, while recent news highlights its sensitivity to Tesla-specific catalysts like the Cybercab event. Financial ratios are not applicable as this is a leveraged ETF tracking Tesla's daily performance.
The outlook for TSLL is directly tied to Tesla's stock momentum, offering potential for magnified gains but carrying high risk from daily rebalancing and volatility decay. Investors face significant downside risk if Tesla trends lower, making it suitable only for short-term, risk-tolerant traders monitoring Tesla's news flow.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →